<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>790</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>12413838</PubmedId>
            <Abstract>To answer the question whether or not T cells to immunodominant protein fragments recognize glycosylated antigens, we synthesized a series of glycopeptides corresponding to peptide 31D, a major T-helper cell epitope of the rabies virus nucleoprotein. Thr4 of the epitope is known to allow mono- or disaccharide side-chain substitutions in either alpha- or beta-anomeric configuration without interfering with MHC-binding. To model naturally occurring glycoprotein fragments that carry extended sugar chains, we prepared Fmoc-Ser/Thr-OPfp building blocks containing alpha- and beta-linked linear tri- and heptasaccharides. Peptide 31D was synthesized with the complex carbohydrates attached to Thr4, and the T-helper cell activity of the glycopeptides was determined. Addition of alpha-linked carbohydrates, that mimic most of the natural O-linked glycoproteins, resulted in a major drop in the T-cell stimulatory ability in a sugar length-dependent manner. In contrast, the cytosolic glycoprotein mimicking beta-linked glycopeptides retained their T-cell stimulatory activity, with the trisaccharide-containing analogue being almost as potent as the unglycosylated peptide. When the peptides were preincubated with diluted human serum, all peptides lost their ability to stimulate the 9C5.D8-H hybridoma. These findings indicated that (i) in contrast to cytosolic glycosylation, incorporation of long O-linked carbohydrates into T-helper cell epitopes abrogates the antigenicity of these protein fragments, and (ii) glycosylation is not a viable alternative to improve the immunogenic properties of subunit peptide vaccines. Glycosylation with all four carbohydrate moieties similarly destroyed the inducible alpha-helical structure of peptide 31D as detected by CD, indicating that the differences in the T-cell activity were not due to different peptide conformations.</Abstract>
            <ArticleYear>2002</ArticleYear>
            <ArticlePages>3859-70</ArticlePages>
            <ArticleTitle>Synthesis, conformation and T-helper cell stimulation of an O-linked glycopeptide epitope containing extended carbohydrate side-chains.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Cudic</LastName>
                    <ForeName>Mare</ForeName>
                </Author>
                <Author>
                    <LastName>Ertl</LastName>
                    <ForeName>Hildegund C J</ForeName>
                </Author>
                <Author>
                    <LastName>Otvos</LastName>
                    <ForeName>Laszlo</ForeName>
                    <Suffix>Jr</Suffix>
                </Author>
            </Authors>
            <Affiliations>The Wistar Institute, Philadelphia, PA 19104, USA.</Affiliations>
            <ArticleChemicalList>Epitopes, T-Lymphocyte;Glycopeptides;Immunodominant Epitopes;Nucleoproteins;Oligosaccharides;peptide 31D</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Carbohydrate Conformation; Epitopes, T-Lymphocyte(chemistry); Glycopeptides(chemical synthesis; chemistry; immunology); Glycosylation; Hybridomas(immunology); Immunity, Cellular(drug effects); Immunodominant Epitopes(chemistry); Lymphocyte Activation(drug effects; immunology); Mice; Mice, Inbred C3H; Molecular Sequence Data; Nucleoproteins(chemistry); Oligosaccharides(chemistry); Structure-Activity Relationship; T-Lymphocytes, Helper-Inducer(drug effects; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>10</Volume>
                <Issue>12</Issue>
                <Title>Bioorganic &amp; medicinal chemistry</Title>
                <Issn>1464-3391</Issn>
                <MedlineTa>Bioorg Med Chem</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>31D</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AVYTRIMMNGGRLKR</LinearSequence>
                        <StartingPosition>404</StartingPosition>
                        <EndingPosition>418</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P16285.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11293</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 2</LocationOfData>
                <EpitopeId>5638</EpitopeId>
                <ReferenceStartingPosition>404</ReferenceStartingPosition>
                <ReferenceEndingPosition>418</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Unmodified version Rabies virus nucleoprotein epitope.  T4 of eptiope is known to allow mono- or di-saccharide side chain substitutions in the α- and β-linked anomers without interfering with MHC binding.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>8247</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000038</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11295</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated Rabies Virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>The 9C5.D8.H cell line was a fusion product between a thymoma cell line and splenocytes from C3H/He mice immunized with inactivated rabies virus of the Evelyn-Rokitnicki-Abelseth (ERA) strain.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (Hybridoma)</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>118</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>31D</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AVYTRIMMNGGRLKR</LinearSequence>
                                        <StartingPosition>404</StartingPosition>
                                        <EndingPosition>418</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P16285.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11293</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Stimulation of 9C5.D8.H T-cell hybridomas with synthetic peptide was performed. This construct (non-glycosylated) gave very robust responses at all three tested concentrations of peptide (5, 1, and 0.2 μg/ml).  The unmodified contruct gave a significantly higher response at the 0.2 μg/ml level than all other glycosylated constructs tested.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>31D-Tβ-(Glc)&lt;sub&gt;3&lt;/sub&gt;</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AVYTRIMMNGGRLKR</LinearSequence>
                        <ModifiedResidues>T4</ModifiedResidues>
                        <Modifications>Glycosylation</Modifications>
                        <StartingPosition>404</StartingPosition>
                        <EndingPosition>418</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>BAC07527.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11293</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 2</LocationOfData>
                <EpitopeId>5637</EpitopeId>
                <ReferenceStartingPosition>404</ReferenceStartingPosition>
                <ReferenceEndingPosition>418</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>This construct utilizes a chemically synthesized (glycoslyated) Thr 4 side-chain:  Glc(α1→4)Glc(α1→4)Glc(β1→O).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>8249</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000038</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11295</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated Rabies virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>The 9C5.D8.H cell line was a fusion product between a thymoma cell line and splenocytes from C3H/He mice immunized with inactivated rabies virus of the Evelyn-Rokitnicki-Abelseth (ERA) strain.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (Hybridoma)</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>118</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>31D-Tβ-(Glc)&lt;sub&gt;3&lt;/sub&gt;</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AVYTRIMMNGGRLKR</LinearSequence>
                                        <ModifiedResidues>T4</ModifiedResidues>
                                        <Modifications>Glycosylation</Modifications>
                                        <StartingPosition>404</StartingPosition>
                                        <EndingPosition>418</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>BAC07527.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11293</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Stimulation of 9C5.D8.H T-cell hybridomas with synthetic peptide was performed. This construct elicited very robust proliferative responses at all three tested concentrations of peptide (5, 1, and 0.2 μg/ml). This β-linked trisaccharide was only the glycosylated analog that elicited a stonger proliferation response at 5 and 1 μg/ml concentrations than the unmodified epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>31D-Tα-(Glc)&lt;sub&gt;2&lt;/sub&gt;GalNAc</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AVYTRIMMNGGRLKR</LinearSequence>
                        <ModifiedResidues>T4</ModifiedResidues>
                        <Modifications>Glycosylation</Modifications>
                        <StartingPosition>404</StartingPosition>
                        <EndingPosition>418</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>BAC07527.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11293</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 2</LocationOfData>
                <EpitopeId>5637</EpitopeId>
                <ReferenceStartingPosition>404</ReferenceStartingPosition>
                <ReferenceEndingPosition>418</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>This construct utilizes a chemically synthesized (glycoslyated) Thr 4 side-chain:  Glc(α1-4)Glc(β1-4)GalNAc(α1-O).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>8250</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000038</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11295</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated Rabies virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>The 9C5.D8.H cell line was a fusion product between a thymoma cell line and splenocytes from C3H/He mice immunized with inactivated rabies virus of the Evelyn-Rokitnicki-Abelseth (ERA) strain.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (Hybridoma)</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>118</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>31D-Tα-(Glc)&lt;sub&gt;2&lt;/sub&gt;GalNAc</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AVYTRIMMNGGRLKR</LinearSequence>
                                        <ModifiedResidues>T4</ModifiedResidues>
                                        <Modifications>Glycosylation</Modifications>
                                        <StartingPosition>404</StartingPosition>
                                        <EndingPosition>418</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>BAC07527.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11293</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Stimulation of 9C5.D8.H T-cell hybridomas with synthetic peptide was performed. This construct gave lower proliferative responses at all three tested concentrations of glycopeptide (5, 1, and 0.2 μg/ml) compared to the unmodified construct.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>31D-Tβ-(Glc)&lt;sub&gt;7&lt;/sub&gt;</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AVYTRIMMNGGRLKR</LinearSequence>
                        <StartingPosition>404</StartingPosition>
                        <EndingPosition>418</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>BAC07527.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11293</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 2</LocationOfData>
                <EpitopeId>5638</EpitopeId>
                <ReferenceStartingPosition>404</ReferenceStartingPosition>
                <ReferenceEndingPosition>418</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>This construct utilizes a chemically synthesized (glycoslyated) Thr 4 side-chain:  [Glc(α1-4)-Glc]&lt;sub&gt;3&lt;/sub&gt;-Glc(β1-O).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>8251</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000038</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11295</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated Rabies virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>The 9C5.D8.H cell line was a fusion product between a thymoma cell line and splenocytes from C3H/He mice immunized with inactivated rabies virus of the Evelyn-Rokitnicki-Abelseth (ERA) strain.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (Hybridoma)</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>118</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>31D-Tβ-(Glc)&lt;sub&gt;7&lt;/sub&gt;</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AVYTRIMMNGGRLKR</LinearSequence>
                                        <StartingPosition>404</StartingPosition>
                                        <EndingPosition>418</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>BAC07527.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11293</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Stimulation of 9C5.D8.H T-cell hybridomas with synthetic peptide was performed. This construct gave lower proliferative responses at all three tested concentrations of glycopeptide (5, 1, and 0.2 μg/ml) compared to the unmodified epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>31D-Tα-(Glc)&lt;sub&gt;6&lt;/sub&gt;GalNAc</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AVYTRIMMNGGRLKR</LinearSequence>
                        <StartingPosition>404</StartingPosition>
                        <EndingPosition>418</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>BAC07527.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11293</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 2</LocationOfData>
                <EpitopeId>5638</EpitopeId>
                <ReferenceStartingPosition>404</ReferenceStartingPosition>
                <ReferenceEndingPosition>418</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>This construct utilizes a chemically synthesized (glycoslyated) Thr 4 side-chain:  [Glc(α1-4)-Glc]&lt;sub&gt;3&lt;/sub&gt;-GalNAc(α1-O).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>8252</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000038</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11295</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated Rabies virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>The 9C5.D8.H cell line was a fusion product between a thymoma cell line and splenocytes from C3H/He mice immunized with inactivated rabies virus of the Evelyn-Rokitnicki-Abelseth (ERA) strain.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (Hybridoma)</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>118</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>31D-Tα-(Glc)&lt;sub&gt;6&lt;/sub&gt;GalNAc</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AVYTRIMMNGGRLKR</LinearSequence>
                                        <StartingPosition>404</StartingPosition>
                                        <EndingPosition>418</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>BAC07527.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11293</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Stimulation of 9C5.D8.H T-cell hybridomas with synthetic peptidewas performed. This construct elicited the weakest proliferative response at all three tested concentrations of glycopeptide (5, 1, and 0.2 μg/ml) compared to other glycosylated constructs and the unmodified contruct.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

